A Diagnostics & Imaging Week

LineaGen (Salt Lake City), a biomarker discovery company created to discover and commercialize significant molecular diagnostic innovations in a variety of healthcare areas, reported the company’s launch with the close of a $5.8 million Series A funding round led by vSpring Capital and Sanderling Biomedical Ventures. Mesa Verde Venture Partners was the third strategic investment partner in the round.

The company said that the capital raised will be used to establish a world-class molecular diagnostic commercialization entity for exploration into the nature, causes and treatment of some of the world’s most pressing medical and healthcare challenges.

LineaGen’s initial focus includes diagnostic tools for the advancement of personalized healthcare by furthering genetic understanding, diagnosis and targeted treatment of significant disorders and diseases, including autism, multiple sclerosis, osteoporosis and chronic obstructive pulmonary disease.

The company has named Dinesh Patel of vSpring, Fred Middleton of Sanderling and Dan Wood of Mesa Verde to the company’s board.

One of LineaGen’s core competitive advantages, according to the company, is its access to an “unmatched biomarker discovery research platform,” used to help the University of Utah (Salt Lake City) identify more disease-related genes than any other institution in the world, and the multi-generational Utah Population Database is “the world’s most comprehensive population and medical database” — comprised of more than 10 million records relating to more than 6 million individuals in Utah, Idaho and surrounding regions.